DOI QR코드

DOI QR Code

Outcome of Staged Repair of Tetralogy of Fallot with Pulmonary Atresia and a Ductus-dependent Pulmonary Circulation: Should Primary Repair Be Considered?

  • Kim, Hyung-Tae (Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital) ;
  • Sung, Si-Chan (Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital) ;
  • Chang, Yun-Hee (Department of Thoracic and Cardiovascular Surgery, The Catholic University of Korea Seoul St. Mary's Hospital) ;
  • Jung, Won-Kil (Department of Thoracic and Cardiovascular Surgery, Pusan National University School of Medicine) ;
  • Lee, Hyoung-Doo (Department of Pediatrics, Pusan National University Yangsan Hospital) ;
  • Park, Ji-Ae (Department of Pediatrics, Pusan National University Yangsan Hospital) ;
  • Huh, Up (Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital)
  • Received : 2011.06.27
  • Accepted : 2011.08.24
  • Published : 2011.12.05

Abstract

Background: The tetralogy of Fallot (TOF) with pulmonary atresia (PA) and a ductus-dependent pulmonary circulation (no major aorto-pulmonary collateral arteries (MAPCAs)) has been treated with staged repair or primary repair depending on the preference of surgeons or institutions. We evaluated the 19-year outcome of staged repair for this anomaly to find out whether our surgical strategy should be changed. Materials and Methods: Forty-four patients with TOF/PA with patent ductus arteriosus (PDA) who underwent staged repair from June 1991 to October 2010 were included in this retrospective study. The patients with MAPCAs were excluded. The average age at the first palliative shunt surgery was $40.8{\pm}67.5$ days (range: 0~332 days). Thirty-one patients (31/44, 70%) were neonates. The average weight was $3.5{\pm}1.6$ kg (range: 1.6~8.7 kg). A modified Blalock-Taussig (BT) shunt was performed in 38 patients, classic BT shunt in 4 patients, and central shunt in 2 patients. Six patients required concomitant procedures: pulmonary artery angioplasty was performed in 4 patients, pulmonary artery reconstruction in one patient, and re-implantation of the left pulmonary artery to the main pulmonary artery in one patient. Four patients required a second shunt operation before the definitive repair was performed. Thirty-three patients underwent definitive repair at $24.2{\pm}13.3$ months (range: 7.3~68 months) after the first palliative operation. The average age at the time of definitive repair was $25.4{\pm}13.5$ months (range: 7.6~68.6 months) and their average weight was $11.0{\pm}2.1$ kg. For definitive repair, 3 types of right ventricular outflow procedures were used: extra-cardiac conduit was performed in 30 patients, trans-annular patch in 2 patients, and REV operation in 1 patient. One patient was lost to follow-up after hospital discharge. The mean follow-up duration for the rest of the patients was $72{\pm}37$ months (range: 4~160 months). Results: Ten patients (10/44, 22.7%) died before the definitive repair was performed. Four of them died during hospitalization after the shunt operation. Six deaths were thought to be shunt-related. The average time of shunt-related deaths after shunt procedures was 8.7 months (range: 2 days~25.3 months). There was no operative mortality after the definitive repair, but one patient died from dilated cardiomyopathy caused by myocarditis 8 years and 3 months after the definitive repair. Five-year and 10-year survival rates after the first palliative operation were 76.8% and 69.1%, respectively. Conclusion: There was a high overall mortality rate in staged repair for the patients with TOF/PA with PDA. Majority of deaths occurred before the definitive repair was performed. Therefore, primary repair or early second stage definitive repair should be considered to enhance the survival rate for patients with TOF/PA with PDA.

Keywords

References

  1. Hirsch JC, Mosca RS, Bove EL. Complete repair of tetralogy of Fallot in the neonate: results in the modern era. Ann Surg 2000;232:508-14. https://doi.org/10.1097/00000658-200010000-00006
  2. Jonas RA. Early primary repair of tetralogy of Fallot. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2009;39-47.
  3. Kwak JG, Lee CH, Lee C, Park CS. Surgical management of pulmonary atresia with ventricular septal defect: early total correction versus shunt. Ann Thorac Surg 2011;91: 1928-34; discussion 34-5. https://doi.org/10.1016/j.athoracsur.2011.01.014
  4. Park CS, Kim WH, Kim GB, et al. Symptomatic young infants with tetralogy of fallot: one-stage versus staged repair. J Card Surg 2010;25:394-9. https://doi.org/10.1111/j.1540-8191.2010.01053.x
  5. Arciniegas E, Farooki ZQ, Hakimi M, Green EW. Results of two-stage surgical treatment of tetralogy of Fallot. J Thorac Cardiovasc Surg 1980;79:876-83.
  6. Stephenson LW, Friedman S, Edmunds LH Jr. Staged surgical management of tetralogy of Fallot in infants. Circulation 1978;58:837-41. https://doi.org/10.1161/01.CIR.58.5.837
  7. Guyton RA, Owens JE, Waumett JD, Dooley KJ, Hatcher CR Jr, Williams WH. The Blalock-Taussig shunt. Low risk, effective palliation, and pulmonary artery growth. J Thorac Cardiovasc Surg 1983;85:917-22.
  8. Stanley PH, Chartrand C, Davignon A, et al. Palliative surgery in tetralogy of Fallot. Can J Surg 1981;24:475-9.
  9. Yuan SM, Shinfeld A, Raanani E. The Blalock-Taussig shunt. J Card Surg 2009;24:101-8. https://doi.org/10.1111/j.1540-8191.2008.00758.x
  10. Swain SK, Dharmapuram AK, Reddy P, Ramdoss N, Raghavan SS, Kona SM. Neonatal Blalock-Taussig shunt: technical aspects and postoperative management. Asian Cardiovasc Thorac Ann 2008;16:7-10. https://doi.org/10.1177/021849230801600103
  11. Gladman G, McCrindle BW, Williams WG, Freedom RM, Benson LN. The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot's tetralogy in the current era. J Thorac Cardiovasc Surg 1997;114:25-30. https://doi.org/10.1016/S0022-5223(97)70113-2
  12. Ahmad U, Fatimi SH, Naqvi I, et al. Modified Blalock- Taussig shunt: immediate and short-term follow-up results in neonates. Heart Lung Circ 2008;17:54-8. https://doi.org/10.1016/j.hlc.2007.06.003
  13. MacMillan M, Jones TK, Lupinetti FM, Johnston TA. Balloon angioplasty for Blalock-Taussig shunt failure in the early postoperative period. Catheter Cardiovasc Interv 2005; 66:585-9. https://doi.org/10.1002/ccd.20438
  14. Van Arsdell G, Yun TJ. An apology for primary repair of tetralogy of Fallot. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2005;128-31.
  15. Pigula FA, Khalil PN, Mayer JE, del Nido PJ, Jonas RA. Repair of tetralogy of Fallot in neonates and young infants. Circulation 1999;100:II157-61. https://doi.org/10.1161/01.CIR.100.25.e157
  16. Metras D, Chetaille P, Kreitmann B, Fraisse A, Ghez O, Riberi A. Pulmonary atresia with ventricular septal defect, extremely hypoplastic pulmonary arteries, major aorto-pulmonary collaterals. Eur J Cardiothorac Surg 2001;20:590-6; discussion 6-7. https://doi.org/10.1016/S1010-7940(01)00855-7

Cited by

  1. Neonatal right ventricle to pulmonary connection as a palliative procedure for pulmonary atresia with ventricular septal defect or severe tetralogy of Fallot vol.45, pp.2, 2011, https://doi.org/10.1093/ejcts/ezt401
  2. Systemic to Pulmonary Artery Versus Right Ventricular to Pulmonary Artery Shunts for Patients With Pulmonary Atresia, Ventricular Septal Defect, and Hypoplastic Pulmonary Arteries vol.30, pp.11, 2011, https://doi.org/10.1111/jocs.12634
  3. Right Ventricle-to-Pulmonary Artery Shunt in Pulmonary Atresia with a Ventricular Septal Defect: A Word of Caution vol.38, pp.4, 2017, https://doi.org/10.1007/s00246-017-1570-4
  4. Outcome of neonatal palliative procedure for pulmonary atresia with ventricular septal defect or tetralogy of Fallot with severe pulmonary stenosis: experience in a single tertiary center vol.61, pp.7, 2018, https://doi.org/10.3345/kjp.2018.61.7.210
  5. Tangeretin: a mechanistic review of its pharmacological and therapeutic effects vol.31, pp.4, 2011, https://doi.org/10.1515/jbcpp-2019-0191
  6. Tangeretin: a mechanistic review of its pharmacological and therapeutic effects vol.31, pp.4, 2011, https://doi.org/10.1515/jbcpp-2019-0191
  7. Phytowaste as nutraceuticals in boosting public health vol.7, pp.1, 2021, https://doi.org/10.1186/s40816-021-00260-w